Davis Yang | Global Strategic Initiatives and Asia Chief Business Officer at Oculis SA
Davis Yang is Global Strategic Initiatives and Asia Chief Business Officer at Oculis SA, a biotech company developing sight-saving medicines. Over his 16 years of experience as a healthcare venture investor and strategic planner, he has played a key role in deploying over $230 million in healthcare companies as well as in raising $600 million in VC funds.
Before joining Oculis, Davis was an investor at Pivotal Life Sciences since its inception, and helped to build out the firm’s strategy, deal pipeline, and investments across company launches, venture deals, and growth investing in life sciences and healthcare in North America, Europe, and China. Prior to that, Davis was a Managing Director with BioVeda China Fund (BVCF Management), one of the first and leading life sciences-focused venture funds based in China, where he led deals in US and China biotech companies and led the build out of the firm’s fundraising function. Prior to that, Davis was a strategic planner at Memorial-Sloan Kettering Cancer Center, where he worked with senior leadership on decision-making for expansions and operational optimizations. Davis has served on the Boards of MicuRx Pharmaceuticals and Nuelle, and as an observer on the Board of Clarus Therapeutics (NASDAQ: CRXT).
Davis earned his MBA at the University of Chicago Booth School of Business, and completed his undergraduate studies at Yale University.
* Mr. Yang is attending the forum as a private citizen, not in affiliation with any official status